BioWorld MedTech

Oct. 26, 2011

Accuray gains approval for TomoTherapy DCS component

Accuray (Sunnyvale, California) reported that FDA has granted it 510(k) clearance to market its Dose Control System (DCS), a new feature for Accuray's TomoTherapy device that is said to improve system performance. Read More

French Radiology Congress: The dark horse in PACS, can France take the lead?

Report from Europe: Epigenomics launches Epi proColon 2.0 CE in Europe

Washington roundup: MDT has good efficacy, iffy safety data for Frontiers PMA

Agreements/contracts: Foundation reports collaboration on cancer genomic test with J&JPRD

Financings roundup: EGHC gains new investors to help boost funding drive

Clarification

Court report: DaVita to receive inquiry from HHS on dialysis drug payments

People in the News

Grants roundup: NERI wins $45 million grant for Pediatric Heart Network

Patent roundup: Daxcor reports filing for albumin measurement instrument patent

Product Briefs

MDD's Oncology Extra

Today's news in brief

BioWorld

BioWorld briefs for May 22, 2026.

Sangamo presents primate data for prion suppressor ST-506

BioWorld Science

Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...

TREM2 agonists detailed in Pfizer patent

BioWorld Science

Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.

Unmasking the X: EPAC2 shifts the fragile X landscape

BioWorld

Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...

Recludix presents STAT1/3 inhibitors for dermatological diseases

BioWorld Science

Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.